Pernille Poulsen

Pernille Poulsen, MD, PhD, DMSc, currently serves as Corporate Vice President of Clinical Development & Regulatory Affairs for Novo Nordisk, holding various leadership roles since November 2008, including overseeing clinical trial executions, regulatory submissions, and medical education across the Europe and Canada regions. With extensive experience in medical and scientific expertise related to global clinical development, particularly within the insulin degludec portfolio, Pernille has managed numerous clinical trials and regulatory interactions across multiple regions, including the US, EU, China, and Japan. Previously, Pernille held academic and medical positions at the University of Copenhagen and Steno Diabetes Center, and has authored research in the field of endocrinology and diabetes. Education credentials include MD, PhD, and DMSc degrees from the University of Southern Denmark, along with business studies at Copenhagen Business School.